

or effectiveness concerns. Third, FDA has independently evaluated relevant literature and internal agency data for possible postmarketing reports associated with cyclophosphamide for injection, and has found no information that would indicate this product was withdrawn for reasons of safety or effectiveness.

After considering the citizen petition and reviewing its records, FDA determines that, for the reasons outlined above, Bristol's cyclophosphamide for injection was not withdrawn from sale for reasons of safety or effectiveness. Thus, FDA will not initiate proceedings to suspend the approvals of ANDAs referencing cyclophosphamide for injection. However, because Bristol has supplemented its CYTOXAN NDA and obtained approval for a new formulation, cyclophosphamide lyophilized, any unapproved ANDAs seeking to reference CYTOXAN (NDA 12-142 054) must reference the currently approved formulation.

Dated: February 15, 2004.

Jeffrey Shuren,

Assistant Commissioner for Policy.

[FR Doc. 04-4505 Filed 2-27-04; 8:45 am]

BILLING CODE 4160-01-S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Health Resources and Services Administration

Cancellation of Grant Opportunities Previously Announced in the HRSA Preview on September 4, 2003 (68 FR 52632)

AGENCY: Health Resources and Services Administration (HRSA), HHS.

ACTION: Notice of cancellation.

SUMMARY: The Health Resources and Services Administration (HRSA) announces the cancellation of eight grant opportunities that were initially published in the (September 4, 2003 (68 FR 52632)) **Federal Register** notice of availability of competitive grant funds for numerous HRSA programs.

EFFECTIVE DATE: March 1, 2004.

FOR FURTHER INFORMATION CONTACT: Gail Lipton, Director, Division of Grants Policy, Office of Financial Policy and Oversight, Telephone (301) 443-6509. (This is not a toll-free number).

SUPPLEMENTARY INFORMATION: The HRSA Preview is a comprehensive listing of HRSA competitive grant programs scheduled for award in Fiscal Year 2004. However, as indicated in the

Frequently Asked Questions section of the Preview, programs may be withdrawn from competition. Based on final Fiscal Year 2004 appropriations and a redirection of priorities, HRSA hereby withdraws the following programs and announcements from Fiscal Year 2004 competition:

HRSA-04-021 Bioterrorism Training and Curriculum Development (BTCDDP).

HRSA-04-028 Radiation Exposure Screening and Education Program (RESEP).

HRSA-04-036 National Health Center Technical Assistance Cooperative Agreements (NAT).

HRSA-04-046 Telehealth Resource Centers Cooperative Agreement Program (TRCCP).

HRSA-04-049 Title III: Early Intervention Services Planning Grants (EISPG).

HRSA-04-052 Maternal and Child Health Minority Research Infrastructure Support Program (RMIN).

HRSA-04-061 Partnership for Information and Communication (PIC) Cooperative Agreement Program.

HRSA-04-074 Best Practices to Increase Organ Donation (HIP).

These cancellations will be effective immediately upon publication of this **Federal Register** notice. HRSA will not accept any FY 2004 competitive applications for these funding opportunities, and any applications previously submitted will be returned to the respective applicants. Further information about HRSA programs will be provided through the HRSA Preview at the HRSA Home page at <http://www.hrsa.gov>.

Dated: February 24, 2004.

Elizabeth M. Duke,

Administrator.

[FR Doc. 04-4506 Filed 2-27-04; 8:45 am]

BILLING CODE 4165-15-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Office of the Director; Notice of Meeting

The Office of the Director, National Institutes of Health (NIH), announces a meeting of the NIH Blue Ribbon Panel on Conflict of Interest Policies, a working group of the Advisory Committee to the Director, NIH. The meeting is scheduled for March 1-2, 2004, beginning at 8:30 a.m. each day.

The meeting will be held at the NIH, 9000 Rockville Pike, Bethesda, Maryland, Building 31C, Conference Room 10. Attendance will be limited to space available. In the interest of security, NIH has instituted stringent procedures for entrance into the building by non-government employees. Persons without a government I.D. will need to show a photo I.D. and sign-in at the security desk upon entering the building.

On March 1 and until noon on March 2, the meeting will be open to the public. Sessions will include: Federal Conflict of Interest Policies; HHS Conflict of Interest Policies, NIH Conflict of Interest Policies and Procedures, and there will be time set aside for oral presentations by the public. Any person wishing to make a presentation should notify Charlene French, Office of Science Policy, National Institutes of Health, Building 1, Room 103, Bethesda, Maryland 20892, telephone 301-496-2122 by February 26, 2004 or by e-mail: blueribbonpanel@mail.nih.gov.

Oral comments will be limited to 5 minutes. Due to time constraints, only one representative from each organization will be allotted time or oral testimony. The number of speakers and the time allotment may also be limited by the number of presentations. The opportunity to speak will be based on a first come first served basis. All requests to present oral comments should include the name, address, telephone number, and business or professional affiliation of the interested party, and should indicate the areas of interest or issue to be addressed. Please provide, if possible, an electronic copy of your comments.

Any person attending the meeting who has not registered to speak in advance of the meeting will be allowed to make a brief oral statement during the time set aside for public comment, if time permits and at the discretion of the co-chairs.

Individuals who plan to attend the meeting and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify Charlene French in advance of the meeting at the address listed earlier in this notice.

Dated: February 19, 2004.

LaVerne Stringfield,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 04-4528 Filed 2-26-04; 11:15 am]

BILLING CODE 4140-01-M